חזרה לתוצאות החיפוש

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Hepatocellular Carcinoma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama, United States

    Contact: Study coordinator (Kiaron Saxton) · klsaxton@uabmc.edu · 205-767-7914

  • University of California San Diego, La Jolla, California, United States

  • Norris Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Rabia Rehman) · Rabia.Rehman@med.usc.edu

  • University of California Irvine Medical Center, Orange, California, United States

    Contact: Study coordinator (Jasmin Balangue) · ucstudy@hs.uci.edu · 877-827-8839

  • University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States

    Contact: Study coordinator (Jeniffer Choi) · Jeniffer.choi@cuanschutz.edu · 303-724-9833

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Cheyenne Schneider) · Cheyenne.Schneider@moffitt.org · 813-745-5166

  • The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

    Contact: Study coordinator (Marina Baretti) · mbarett1@jhu.edu · 410-614-4626

  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

    Contact: Study coordinator (University of Michigan Rogel Cancer Center) · CancerAnswerLine@med.umich.edu · 800-865-1125

  • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Mohammed Najeeb Al Hallak, MD) · 800-527-6266

  • Washington University in St. Louis, St Louis, Missouri, United States

    Contact: Study coordinator (Hailey Sappington, MPH) · hailey@wustl.edu · 314-362-2582
    Contact: Study coordinator (Mina Abdiannia) · mina.a@wustl.edu · 314-273-2804

  • Memorial Sloan Kettering Cancer Center - New York, New York, New York, United States

    Contact: Study coordinator (James Harding)

  • Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States

    Contact: Study coordinator (Cancer Answer Line) · 877-585-8523

  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Susanna Ulahannan, MD) · susanna-ulahannan@ouhsc.edu · 405-271-8001

  • Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States

    Contact: Study coordinator (Carrie Manwaring) · Carrie.Manwaring@UTSouthwestern.edu · 214-645-9685

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (MD Anderson Cancer Center) · GIClinicalTrials@mdanderson.org

  • DHR Health Institute for Research and Development, McAllen, Texas, United States

    Contact: Study coordinator (Jose Cruz, DO) · jose.cruz@dhr-rgv.com
    Study coordinator · jose.cruz@dhrhealth.com

  • University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Research Department) · mccresearch@uthscsa.edu · 210-450-1000

  • Virginia Mason Medical Center, Seattle, Washington, United States

    Contact: Study coordinator (Marie Hwang) · 206-287-6280

  • Summit Cancer Centers - North Spokane, Spokane, Washington, United States

    Contact: Study coordinator (Monika Chaudhry, PhD, CCRC) · mchaudhry@summitcancercenters.com · 509-462-2273

  • Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, United States

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)